Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

Review

Involvement of α6β4 integrin in the mechanisms that regulate breast cancer progression

Giulia Bon, Valentina Folgiero, Selene Di Carlo, Ada Sacchi and Rita Falcioni*

Author Affiliations

Regina Elena Cancer Institute, Department of Experimental Oncology, Molecular Oncogenesis Laboratory, Via delle Messi d'Oro, 00158 Rome, Italy

For all author emails, please log on.

Breast Cancer Research 2007, 9:203  doi:10.1186/bcr1651

The electronic version of this article is the complete one and can be found online at: http://breast-cancer-research.com/content/9/1/203


Published:23 February 2007

© 2007 BioMed Central Ltd

Abstract

Integrin α6β4 is mostly expressed in epithelial tissues and endothelial and Schwann cells. Expression of α6β4 is increased in many epithelial tumours, implicating its involvement in tumour malignancy. Moreover, this integrin activates several key signalling molecules in carcinoma cells, but its ability to activate the phosphatidylinositol 3-kinase/Akt pathway is among the mechanisms by which α6β4 integrin regulates tumour behaviour. In this review we discuss the biological and clinical features of α6β4 integrin that allow it to promote tumour survival and progression of mammary tumours.

Introduction

Integrins belong to a family of heterodimer transmembrane receptors whose major function is to mediate adhesion and migration through extracellular matrix components [1,2]. They also regulate other processes such as cell proliferation, growth and differentiation [3]. Studies conducted during the past 10 years have provided evidence that integrins are involved in mechanisms that influence tumour progression by activating various intracellular signalling pathways [4].

Among the integrin family of receptors, α6β4 integrin was initially identified as tumour-specific antigen-180 [5]. A subsequent study [6] demonstrated the true identity of tumour-specific antigen-180 to be α6β4 integrin. In most epithelial tissues, including mammary epithelium, the distribution of α6β4 integrin is restricted to the basal layer [7,8], where it participates in the formation and stabilization of hemidesmosomes [9]. Most epithelial tumours lack hemidesmosomes, and α6β4 integrin is distributed diffusely over the cell surface; the markedly increased expression of α6β4 integrin in this setting suggests that it is involved in tumour progression [10,11]. Direct involvement of this integrin in tumour progression was first demonstrated by the finding that de novo expression of the β4 integrin subunit increases the invasive capacity of β4-negative colon carcinoma cells [12]. In mammary tumour cells it has been demonstrated that α6β4 integrin, cooperating with Erb family members, plays an important role in regulating cancer behaviour [10].

Breast cancer is one of the most heterogeneous carcinomas in terms of metastatic capacity, expression of hormone receptors and responsiveness to treatment. In women it is the most common form of cancer and it is the second leading cause of cancer mortality (after lung cancer). It has been demonstrated that in many breast cancers the effect of therapy can be abrogated by high levels of ErbB-2 and vigorous activation of the phosphatidylinositol 3-kinase (PI3K) pathway [13]. Many breast cancer cell lines also exhibit high levels of expression of α6β4 integrin; in these cell lines it has been observed that overexpression of this integrin results in potent activation of specific signalling pathways, especially the PI3K/Akt pathway [14]. These studies have revealed a specific function of α6β4 integrin in tumours and have elucidated the mechanisms by which this integrin promotes the survival and progression of mammary tumours.

Role of α6β4 integrin in cell migration

The altered expression of α6β4 integrin in tumour cell lines of epithelial origin suggests that this integrin promotes tumour progression and spread [14]. Only during the past few years has it become clear how α6β4 integrin contributes to these tumour behaviours. The large cytoplasmic tail of the β4 subunit, which comprises more than 1,000 amino acids, is unique among the integrin family members [15].

Much progress has been made in identifying specific domains that mediate functions such as adhesion and migration in normal and tumour cells [16,17]. Chemotactic migration of carcinoma cells on laminin-1 requires not only the formation of F-actin-rich cell protrusions, which mediate α6β4-dependent cell migration, but also disruption of hemidesmosomes by protein kinase C [18]. Moreover, stimulation of epidermal growth factor causes mobilization of α6β4 integrin from the hemidesmosomes and increases formation of lamellipodia and membrane ruffles that contain α6β4 integrin [18,19]. It has also been shown in keratinocytes that spreading on laminin-5 activates Ron, which results in a protein kinase C dependent translocation of α6β4 integrin from hemidesmosome to lamellipodia [20]; this corroborates previous work in suggesting that α6β4 integrin, by helping to stabilize dynamic structures, promotes migration. In addition, the ability of α6β4 integrin to regulate the expression of genes such as the transcription factor NFAT [21] and the mitogen autotaxin/ENPP2 factor [22] could be among the mechanism through which the integrin can promote breast cancer cell motility.

Another mechanism by which α6β4 integrin could be involved in breast cancer cell invasion is dependent on hypoxia [23]. Hypoxia causes a marked increase in surface expression of α6β4 integrin in mammary tumour cells, which modulates their motility and ability to invade.

Role of α6β4 integrin in PI3K-dependent tumour survival

As in keratinocytes, overexpression of α6β4 integrin in breast cancer cells promotes motility by specifically activating PI3K [24]. In particular, regulation of PI3K by α6β4 stimulation is required for the formation of motility structures and for activation of Rac to promote invasion. It has also been reported that α6β4 integrin promotes survival by activating the PI3K/Akt pathway and that this function may be dependent on p53 status [25]. Specifically, it has been demonstrated that α6β4 can promote PI3K/Akt-dependent survival of p53-deficent mammary tumour cells. Moreover, in response to α6β4 ligation for the recruitment of PI3K on the plasma membrane are implicated two insulin receptor substrate (IRS) members, namely IRS-1 and IRS-2, as adaptor proteins, that mediate the α6β4-dependent PI3K activation [26].

A study conducted in our laboratory [27] provided the first evidence that in mammary tumour cells α6β4 associates with ErbB-2, the orphan receptor of the epidermal growth factor receptor (EGFR) family, which is frequently found to be highly expressed in mammary tumours. A subsequent study conducted in a NIH3T3 cell model system [28] demonstrated that the β4 cytoplasmic tail is required in this interaction and that both α6β4 and ErbB-2 molecules are required for PI3K-dependent invasion. Both β4 integrin subunit and ErbB-2 lack the consensus sequence to bind p85, the regulatory subunit of PI3K; this suggests that involvement of another EGFR family member is required to activate PI3K. Among EGFR family members, the ErbB-2/ErbB-3 heterodimer is the most potent activator of PI3K. α6β4 Integrin and ErbB-2/ErbB-3 have been implicated in breast cancer progression and metastasis [29,30], findings that suggest a role for the ErbB-3 molecule in α6β4/ErbB-2 cooperation. Indeed, α6β4 regulates the translation of ErbB-3 protein in mammary cells, which results in significant induction of ErbB-2/ErbB-3 heterodimerization and consequent activation of the PI3K/Akt survival pathway [31]. Moreover, activation of PI3K/Akt pathway mediated by α6β4 ligation is inhibited upon ErbB-3 depletion, indicating that the survival function of α6β4 integrin is dependent on ErbB-3.

These data are apparently in contrast with the finding that clustering of α6β4 under adherent conditions does not result in significantly increased PI3K activity [32]. However, these latter findings were obtained in a cell line that expresses high levels of α6β4 integrin and that does not express ErbB-3 receptor. A probable explanation for the discrepant observations is that the cells used by Gilcrease and coworkers [32] express the Nrdp1 ubiquitin ligase, which promotes ErbB-3 degradation [33].

Previous work [34] demonstrated that α6β4, through the PI3K/Akt pathway, phosphorylates and inactivates 4E-BP1 (a translational repressor), which in turn stimulates production of vascular endothelial growth factor (VEGF) and promotes survival of breast cancer cells. The VEGF is an autocrine survival factor for breast carcinoma cells [34], and because α6β4 cooperates with EGFR members to promote survival of breast cancer cells [31] we cannot exclude the possibility that ErbB-2/ErbB-3 signalling promotes α6β4-mediated breast carcinoma survival by elevating VEGF expression. It is interesting to note that the crosstalk between α6β4 integrin and EGFR family members is strong. For example, it was recently shown that α6β4 integrin also regulates the translation of ErbB-2 protein and that expression of α6β4 integrin is necessary to regulate Ras activation [35]. Moreover, H-Ras promotes carcinoma invasion by E2F-dependent regulation of α6β4 integrin [36]. Overexpression of E2F family members increases levels of the β4 subunit both at transcriptional and protein levels, resulting in markedly increased invasion.

Role of α6β4 integrin in breast cancer progression

A specific role for α6β4 integrin in breast cancer progression and tumourigenesis was recently demonstrated by the finding that depletion of α6β4 integrin, by RNA interference, strongly reduces in vitro and in vivo tumourigenicity [37,38]. Interestingly, loss of α6β4 integrin reduces significantly the tumourigenicity of mammary tumour cells, reducing the production of VEGF in vivo. This finding is in agreement with previous data indicating that α6β4 integrin regulates VEGF translation [34], supporting the important role played by α6β4 integrin in sustaining the survival of mammary tumour cells [25]. Loss of α6β4 integrin also results in significant downregulation of PI3K/Akt activity [38].

It has been found that in the absence of hormone β4-depleted cells exhibit a 17% rate of apoptosis, which increases to 45% with to hormone therapy [38]. This finding indicates that α6β4 integrin plays a role in promoting survival in mammary tumour cells in the absence of hormone. Recently, it has been described that mice carrying a deletion of the c-terminal region of the β4 tail evidenced that α6β4 integrin promotes mammary tumourigenesis [39]. In vivo, cooperation between α6β4 integrin and ErbB-2 enhances activation of the transcription factors STAT3 and c-Jun, which results in disrupted epithelial polarity and hyperproliferation, respectively [39].

The α6β4 integrin cooperates with other tyrosine kinases such as c-met (a hepatocyte growth factor receptor) to promote invasion [40]. Stimulation with hepatocyte growth factor (c-met kinase) transphosphorylates β4, which associates with Shc and PI3K, potentiating hepatocyte growth factor-triggered signalling on both Ras and PI3K dependent pathways. The same group [41] recently found that over-expression of β4 subunit is sufficient to transform rodent fibroblasts, increases the in vitro growth of mammary tumour cells, and induces tumourigenicity in nude mice, whereas depletion of α6β4 integrin abrogates the transformed phenotype.

Altogether, these studies demonstrate that the crosstalk between α6β4 integrin and receptor tyrosine kinase signalling is strong and contributes to increased ability of mammary tumour cells to grow and invade.

In vivo expression and localization of α6β4 integrin in breast cancer

Although expression of α6β4 integrin in vivo has not been evaluated extensively, the in vivo data obtained in the following studies are in agreement with in vitro findings.

The first study to analyze the distribution of α6β4 integrin in human carcinomas [42] identified high levels ofexpression in various epithelial tumours. Similar findings were reported from a study that analyzed the β4 subunit in normal, hyperplastic and neoplastic breast cancers [43]. Among the tumours analyzed, immunohistochemical study found that mucinous carcinomas are highly positive for β4 expression, whereas luminal cells of normal ducts and acini as well as fibroadenocystic tissue exhibit rare, weak reactivity.

In contrast to previous findings, an analysis conducted in a limited number of breast cancers [44] demonstrated loss of α6β4 integrin in grade III ductal carcinoma (7/11 cases) whereas most of grade I and II carcinomas analyzed were positive (6/8 cases). Even though this study is restricted to a small number of mammary tumours and the results obtained did not achieve statistical significance, it revealed marked deregulation of integrin expression that correlated with loss of polarization, which is a characteristic feature of epithelial tumours. Similar results were obtained in an analysis of the expression of α6 and β4 subunits in primary and metastatic breast cancers [45]. Interestingly, the findings obtained indicate that, as expected, in normal mammary gland both subunits colocalize at the basolateral aspect of the epithelium, which remains unchanged in benign breast lesions; in contrast, in primary carcinomas expression of both chains is reduced and restricted over the cell surface. The same study revealed that α6β4 integrin is present at lymphonodal foci, but that the level of expression is less in metastases to the pleural cavity and parenchymal tissues. Moreover, lack of laminin and collagen type IV correlates in these tumours with reduced α6β4 expression [45].

More recently, a study conducted in 119 tumours from patients with invasive breast carcinoma [46] demonstrated that low levels of expression of α6 subunit correlate with survival, whereas high levels of expression correlate with significantly reduced survival. Indeed, elevated expression of α6 was present in 90% of cases with distant metastases, indicating that this integrin plays a role in tumour progression. In agreement with the findings of that study, an analysis of α6β4 integrin in 80 patients with breast carcinoma [47] revealed that 36 of these tumours expressed high levels of β4 subunit, with a significant association between expression of α6 subunit and production of laminin by tumour cells. That study demonstrated, for the first time, that concomitant expression of α6β4 integrin and laminin production has clear prognostic value, suggesting that these molecules mediate signalling events that are important for tumour progression.

An in situ hybridization study was recently conducted in which β4 mRNA expression was evaluated in paraffin-embedded sections of tissue from 25 patients with invasive breast carcinoma, and compared with immunohistochemical findings from frozen sections derived from same tumours [48]. It revealed that all cases positive for β4 protein also expressed β4 mRNA; three cases in which β4 mRNAwas detected did not express β4 at the protein level. Using in situ hybridization, the same group analyzed β4 subunit mRNA expression in early breast cancer and correlated their findings with both tumour size and nuclear grade [49]. They also analyzed the expression of laminin-5 (the major substrate for α6β4 integrin in epithelial tissue) in these tumours. They observed a strong correlation between β4 mRNA expression and tumour size and nuclear grade, but correlation between β4 and laminin-5 expression was not found to have prognostic significance [50].

All of these studies, in agreement with literature published during the past 2 years, strongly support a role for α6β4 expression in promoting tumour progression. These studies also indicate that the biological role played by α6β4 in mammary tumours is complex; studies should be extended to other molecules that may cooperate with α6β4 integrin to render tumours more aggressive. These studies could help us to determine whether α6β4 integrin should be considered an early marker of tumourigenicity and to evaluate tumour prognosis better.

Conclusion

Both experimental data and in vivo studies discussed in this review indicate that α6β4 integrin plays a major role in mediating the aggressiveness of mammary tumours. Metastasis is a complex process that involves many molecules and many biochemical alterations in tumour cells. Integrin α6β4 is a key molecule in this process, but much more needs to be learned about the contribution of this integrin to tumour progression. There is much cooperation between α6β4 integrin and EGFR family members; furthermore, this integrin can modulate the expression of growth factors and growth factor receptors that are involved in tumour progression. Acknowledgement of the intimate relationships between these molecules could represent an aid in determining prognosis, could guide management decisions, and could facilitate development of drugs with novel targets.

Abbreviations

EGFR = epidermal growth factor receptor; IRS = insulin receptor substrate; PI3K = phosphatidylinositol 3-kinase; VEGF = vascular endothelial growth factor.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

Grant support: Italian Association for Cancer Research (AIRC) and Ministero della Salute (R Falcioni). G Bon is recipient of a fellowship from Federazione Italiana Ricerca sul Cancro (FIRC). The authors are particularly grateful to Dr Arthur M Mercurio for critical reading and helpful suggestions.

References

  1. Hynes RO: Integrins: versatility, modulation, and signalling in cell adhesion.

    Cell 1992, 69:11-25. PubMed Abstract | Publisher Full Text OpenURL

  2. Mercurio AM, Rabinovitz I, Shaw LM: The alpha6beta4 integrin and epithelial cell migration.

    Curr Opin Cell Biol 2001, 13:541-545. PubMed Abstract | Publisher Full Text OpenURL

  3. Watt FM, Kubler MD, Hotchin NA, Nicholson LJ, Adams JC: Regulation of keratinocyte terminal differentiation by integrin-extracellular matrix interaction.

    J Cell Sci 1993, 106:175-182. PubMed Abstract | Publisher Full Text OpenURL

  4. Guo W, Giancotti FG: Integrin signalling during tumor progression.

    Nat Rev Mol Cell Biol 2004, 5:816-826. PubMed Abstract | Publisher Full Text OpenURL

  5. Falcioni R, Sacchi A, Resau J, Kennel SJ: Monoclonal antibody to human carcinoma-associated protein complex: quantitation in normal and tumor tissue.

    Cancer Res 1988, 48:816-821. PubMed Abstract | Publisher Full Text OpenURL

  6. Kennel SJ, Foote LJ, Falcioni R, Sonnenberag A, Stringer CD, Crouse C, Hemler ME: Analysis of the tumor-associated antigen TSP-180. Identity with alpha 6-beta4 in the integrin superfamily.

    J Biol Chem 1989, 264:15515-15521. PubMed Abstract | Publisher Full Text OpenURL

  7. Sonnenberg A, Linders CJ, Daams JH, Kennel SJ: The alpha 6 beta 1 (VLA-6) and alpha 6 beta 4 protein complexes: tissue distribution and biochemical properties.

    J Cell Sci 1990, 96:207-217. PubMed Abstract | Publisher Full Text OpenURL

  8. Streuli CH, Bailey N, Bissell MJ: Control of mammary epithelial differentiation: basement membrane induces tissue-specific gene expression in the absence of cell-cell interaction and morphological polarity.

    J Cell Biol 1991, 115:1383-1395. PubMed Abstract | Publisher Full Text OpenURL

  9. Schaapveld RO, Borradori L, Geerts D, van Leusden MR, Kuikman I, Nievers MG, Niessen CM, Steenbergen RD, Snijders PJ, Sonnenberg A: Hemidesmosomes formation is initiated by b4 integrin subunit, requires complex of b4 and HD1/plectin, and involves a direct interaction between b4 and the bullous pemphigoid antigene 180.

    J Cell Biol 1998, 142:271-284. PubMed Abstract | Publisher Full Text OpenURL

  10. Mercurio AM, Rabinovitz I, Shaw LM: The alpha6beta4 integrin and epithelial cell migration.

    Curr Opin Cell Biol 2001, 13:541-545. PubMed Abstract | Publisher Full Text OpenURL

  11. Wilhelmsen K, Litjens SH, Sonnenberg A: Multiple functions of the integrin α6β4 in epidermal homeostasis and tumorigenesis.

    Mol Cell Biol 2006, 26:2877-2886. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  12. Chao C, Lotz MM, Clarke AC, Mercurio AM: A function for the integrin alpha6beta4 in the invasive properties of colorectal carcinoma cells.

    Cancer Res 1996, 56:4811-4819. PubMed Abstract | Publisher Full Text OpenURL

  13. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors.

    Nat Rev Cancer 2005, 5:341-354. PubMed Abstract | Publisher Full Text OpenURL

  14. Lipscomb EA, Mercurio AM: Mobilization and activation of a signaling competent α6β4 integrin underlines its contributionto carcinoma progression.

    Cancer Metastasis Rev 2005, 24:413-423. PubMed Abstract | Publisher Full Text OpenURL

  15. Hogervorst F, Kuikman I, von dem Borne AE, Sonnenberg A: Cloning and sequence analysis of beta-4 cDNA: an integrin subunit that contains a unique 118 kd cytoplasmic domain.

    EMBO J 1990, 9:765-770. PubMed Abstract | PubMed Central Full Text OpenURL

  16. Borradori L, Sonnenberg A: Hemidesmosomes: roles in adhesion, signaling and human deseases.

    Curr Opin Cell Biol 1996, 8:647-656. PubMed Abstract | Publisher Full Text OpenURL

  17. Wilhelmsen K, Litjiens SH, Sonnenberg A: Multiple functions of the integrin α6β4 in epidermal homeostasis and tumorigenesis.

    Mol Cell Biol 2006, 26:2877-2886. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  18. Rabinovitz I, Toker A, Mercurio AM: Protein kinase C-dependent mobilization of the α6β4 integrin from hemidesmosomes and its association with actin-rich cell protrusions drive the chemotactic migration of carcinoma cells.

    J Cell Biol 1999, 146:1147-1160. PubMed Abstract | Publisher Full Text OpenURL

  19. Gagnoux-Placidos L, Dans M, van'Hof W, Mariotti A, Pepe A, Meneguzzi G, Resh MD, Giancotti FG: Compartmentalization of integrin alpha6beta4 signaling in lipid rafts.

    J Cell Biol 2003, 162:1189-1196. PubMed Abstract | Publisher Full Text OpenURL

  20. Santoro MM, Gaudino G, Marchisio PC: The MSP receptor regulates α6β4 and α6β1 integrins via 14-3-3 protein in keratinocyte migration.

    Dev Cell 2003, 5:257-271. PubMed Abstract | Publisher Full Text OpenURL

  21. Jauliac S, Lòpez-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A: The role of NFAT transcription factors in integrin-mediated carcinoma invasion.

    Nat Cell Biol 2002, 4:540-544. PubMed Abstract | Publisher Full Text OpenURL

  22. Chen M, O'Connor KL: Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells.

    Oncogene 2005, 24:5125-5130. PubMed Abstract | Publisher Full Text OpenURL

  23. Yoon SO, Shin S, Mercurio AM: Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin.

    Cancer Res 2005, 65:2761-2769. PubMed Abstract | Publisher Full Text OpenURL

  24. Shaw LM, Rabinovitz I, Wang HH, Toker A, Mercurio AM: Activation of phosphoinositide 3-OH kinase by the α6β4 integrin promotes carcinoma invasion.

    Cell 1997, 91:949-960. PubMed Abstract | Publisher Full Text OpenURL

  25. Bachelder RE, Ribick MJ, Marchetti A, Falcioni R, Soddu S, Davis KR, Mercurio AM: p53 inhibits α6β4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB.

    J Cell Biol 1999, 147:1063-1072. PubMed Abstract | Publisher Full Text OpenURL

  26. Shaw LM: Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion.

    Mol Cell Biol 2001, 21:5082-5093. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  27. Falcioni R, Antonini A, Nisticò P, Di Stefano S, Crescenzi M, Natali PG, Sacchi A: α6β4 and α6β1 integrins associate with ErbB-2 in human carcinoma cell lines.

    Exp Cell Res 1997, 236:76-85. PubMed Abstract | Publisher Full Text OpenURL

  28. Gambaletta D, Marchetti A, Benedetti L, Mercurio AM, Sacchi A, Falcioni R: Cooperative signaling between alpha6beta4 integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion.

    J Biol Chem 2000, 275:10604-10610. PubMed Abstract | Publisher Full Text OpenURL

  29. Mercurio AM, Bachelder RE, Chung J, O'Connor KL, Rabinovitz I, Shaw LM, Tani T: Integrin laminin receptors and breast carcinoma progression.

    J Mammary Gland Biol Neoplasia 2001, 6:299-309. PubMed Abstract | Publisher Full Text OpenURL

  30. Siegel PM, Ryan ED, Cardiff RD, Muller WJ: Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer.

    EMBO J 1999, 18:2149-2164. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  31. Folgiero V, Bachelder ER, Bon G, Sacchi A, Falcioni R, Mercurio AM: The α6β4 integrin can regulate ErbB-3 expression: implications for α6β4 signaling and function.

    Cancer Res 2007, in press. PubMed Abstract | Publisher Full Text OpenURL

  32. Gilcrease MZ, Zhou X, Welch K: Adhesion-independent alpha6beta4 integrin clustering is mediated by phosphatidylinositol 3-kinase.

    Cancer Res 2004, 64:7395-7398. PubMed Abstract | Publisher Full Text OpenURL

  33. Sweeney C, Carraway KL III: Negative regulation of ErbB family receptor tyrosine kinases.

    Br J Cancer 2004, 90:289-293. PubMed Abstract | Publisher Full Text OpenURL

  34. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM: Integrin (alpha6beta4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells.

    J Cell Biol 2002, 158:165-174. PubMed Abstract | Publisher Full Text OpenURL

  35. Yoon SO, Shin S, Lipscomb EA: A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.

    Cancer Res 2006, 66:2732-2739. PubMed Abstract | Publisher Full Text OpenURL

  36. Yoon SO, Shin S, Mercurio AM: Ras stimulation of E2F activity and a consequent E2F regulation of integrin alpha6beta4 promote the invasion of breast carcinoma cells.

    Cancer Res 2006, 66:6288-6295. PubMed Abstract | Publisher Full Text OpenURL

  37. Lipscomb EA, Simpson KJ, Lyle SR, Ring JE, Dugan AS, Mercurio AM: The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo.

    Cancer Res 2005, 65:10970-10976. PubMed Abstract | Publisher Full Text OpenURL

  38. Bon G, Folgiero V, Bossi G, Felicioni L, Marchetti A, Sacchi A, Falcioni R: The loss of β4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation.

    Clin Cancer Res 2006, 12:3280-3287. PubMed Abstract | Publisher Full Text OpenURL

  39. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghiami G, Giancotti FG: Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.

    Cell 2006, 126:489-502. PubMed Abstract | Publisher Full Text OpenURL

  40. Trusolino L, Bertotti A, Comoglio PM: A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth.

    Cell 2001, 107:643-654. PubMed Abstract | Publisher Full Text OpenURL

  41. Berotti A, Comoglio PM, Trusolino L: Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis.

    Cancer Res 2005, 65:10674-10679. PubMed Abstract | Publisher Full Text OpenURL

  42. Falcioni R, Sacchi A, Resau J, Kennel SJ: Monoclonal antibody to human carcinoma-associate protein complex: quantitation in norma and tumor tissues.

    Cancer Res 1988, 48:816-821. PubMed Abstract | Publisher Full Text OpenURL

  43. Koukoulis GK, Virtanen I, Korhonen M, Laitinen L, Quaranta V, Gould Victor E: Immunohistochemical localization of integrin in the norma, hyperplastic, and neoplastic breast.

    Am J Pathol 1991, 139:787-799. PubMed Abstract OpenURL

  44. Pignatelli M, Cardillo MR, Hanby A, Stamp GVH: Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors.

    Hum Pathol 1992, 23:1159-1166. PubMed Abstract | Publisher Full Text OpenURL

  45. Natali PG, Nicotra MR, Mottolese M, Segatto O: Changes in expression of alpha6/beta4 integrin heterodimer in primary and metastatic breast cancer.

    Br J Cancer 1992, 66:318-322. PubMed Abstract OpenURL

  46. Friedrichs K, Ruiz P, Franke F, Gille I, Terpe H-J, Imhof BA: High expression level of a6 integrin in human breast carcinoma is correlated with reduced survival.

    Cancer Res 1995, 55:901-906. PubMed Abstract | Publisher Full Text OpenURL

  47. Tagliabue E, Ghirelli C, Squicciarini P, Aiello P, Colnaghi MI, Ménard S: Prognostic value of α6β4 integrin expression in breast carcinomas is affected by laminin production from tumor cells.

    Clin Cancer Res 1998, 4:407-410. PubMed Abstract | Publisher Full Text OpenURL

  48. Diaz LK, Zhou X, Welch K, Sabin A, Gilcrease MZ: Chromogenic in situ hybridization for alpha6beta4 integrin in breast cancer: correlation with protein expression.

    J Mol Diagn 2004, 6:10-15. PubMed Abstract | Publisher Full Text OpenURL

  49. Carter WG, Ryan MC, Gahr PJ: Epiligrin, a new cell adhesion ligand for integrin alpha 3 beta 1 in epithelial basement membranes.

    Cell 1991, 65:599-610. PubMed Abstract | Publisher Full Text OpenURL

  50. Diaz LK, Cristofanili M, Zhou X, Welch K, Smith TL, Yang Y, Sahin AA, Gilcrease MZ: Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer.

    Mod Pathol 2005, 18:1165-1175. PubMed Abstract | Publisher Full Text OpenURL